Table 3. The association of XRCC3 Thr241Met polymorphism and survival of NSCLC.
| Heterozygote Comparison | Homozygote Comparison | Dominant Model | |||||||
| Num | HR(95% CI) | P | Num | HR(95% CI) | P | Num | HR(95% CI) | P | |
| Overall | 6 | 1.220 (0.957–1.555) | 0.056 | 4 | 0.891 (0.752–1.056) | 0.222 | 6 | 1.082 (0.929–1.261) | 0.564 |
| Ethnicity | |||||||||
| Asian | 4 | 1.077 (0.798–1.453) | 0.289 | 2 | 0.830 (0.593–1.162) | 0.485 | 5 | 1.047 (0.879–1.248) | 0.503 |
| Caucasian | 1 | 1.500 (1.309–1.719)* | NA | 1 | 0.850 (0.689–1.049) | NA | 1 | 1.200 (0.879–1.638) | NA |
| Mixed | 1 | 1.120 (0.737–1.703) | NA | 1 | 1.540 (0.871–2.723) | NA | NA | NA | NA |
| Treatment | |||||||||
| Pt-Chemo | 4 | 1.155 (0.803–1.662) | 0.017 | 3 | 0.887 (0.737–1.068) | 0.112 | 3 | 0.998 (0.808–1.233) | 0.411 |
| Surgery | 1 | 1.670 (0.750–3.719) | NA | NA | NA | NA | 1 | 1.670 (0.750–3.719) | NA |
| Radio+Chemo | 1 | 1.220 (0.840–1.771) | NA | 1 | 0.910 (0.596–1.390) | NA | 2 | 1.149 (0.913–1.445) | 0.683 |
Heterozygote Comparison: ThrMet vs. ThrThr; Homozygote Comparison: MetMet vs. ThrThr; Dominant Model: ThrMet+MetMet vs. ThrThr; P: p value for heterogeneity; Pt-chemo: platinum-based chemotherapy; Num: number of studies analyzed; Radio+Chemo: radiotherapy + chemotherapy; NA: not available; * significant difference.